Inhibrx Biosciences, Inc.
INBX
$111.66
-$1.21-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.59% | -107.56% | -108.30% | -109.45% | -110.02% |
| Total Depreciation and Amortization | -20.75% | -9.81% | 8.67% | 37.70% | 93.67% |
| Total Amortization of Deferred Charges | 184.99% | 94.54% | 18.11% | -45.74% | -74.53% |
| Total Other Non-Cash Items | 4.56% | 100.68% | 100.67% | 100.68% | 100.67% |
| Change in Net Operating Assets | -286.18% | -141.36% | -114.63% | -107.33% | -88.53% |
| Cash from Operations | 5.69% | 21.12% | 33.24% | 30.90% | 39.58% |
| Capital Expenditure | 96.48% | 99.33% | 98.81% | 99.22% | 95.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 97.54% | 99.53% | 98.92% | 99.27% | 95.69% |
| Total Debt Issued | -24.98% | -24.98% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -93.70% | -97.76% | -99.52% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | 44.44% | 64.79% |
| Cash from Financing | -21.20% | -41.96% | 41.53% | 38.12% | -63.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.09% | -52.55% | 77.36% | 69.33% | -217.24% |